Sinusitis - Pipeline Review, H1 2018 - Product Image

Sinusitis - Pipeline Review, H1 2018

  • ID: 4482757
  • Report
  • 87 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AmpliPhi Biosciences Corp
  • F. Hoffmann-La Roche Ltd
  • Knopp Biosciences LLC
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • OptiNose US Inc
  • MORE
Sinusitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis - Pipeline Review, H1 2018, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.

Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Sinusitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 4, 3 and 1 respectively.

Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AmpliPhi Biosciences Corp
  • F. Hoffmann-La Roche Ltd
  • Knopp Biosciences LLC
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • OptiNose US Inc
  • MORE
Introduction

Report Coverage

Sinusitis - Overview

Sinusitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Sinusitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sinusitis - Companies Involved in Therapeutics Development

AmpliPhi Biosciences Corp

F. Hoffmann-La Roche Ltd

Knopp Biosciences LLC

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Merck & Co Inc

OptiNose US Inc

Pfizer Inc

Quorum Innovations LLC

Therabron Therapeutics Inc

Sinusitis - Drug Profiles

ABSA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexpramipexole dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lascufloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NORS-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCL-1550 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06817024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qi-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Rhinosinusitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sinusitis - Dormant Projects

Sinusitis - Discontinued Products

Sinusitis - Product Development Milestones

Featured News & Press Releases

Feb 27, 2018: Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress

Oct 30, 2017: Optinose Expands Leadership Team with Key Hires

Apr 17, 2017: AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal

Apr 04, 2017: AmpliPhi Biosciences Presents Clinical and Preclinical Data of Pipeline Program AB-SA01 at Two Scientific Conferences

Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials

Dec 19, 2016: AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

Oct 25, 2016: AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis

Sep 20, 2016: AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients

Sep 16, 2016: OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis with and without Nasal Polyps

Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress

Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus

Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort

Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA

Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections

Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Sinusitis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Sinusitis - Pipeline by AmpliPhi Biosciences Corp, H1 2018

Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Sinusitis - Pipeline by Knopp Biosciences LLC, H1 2018

Sinusitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Sinusitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Sinusitis - Pipeline by Merck & Co Inc, H1 2018

Sinusitis - Pipeline by OptiNose US Inc, H1 2018

Sinusitis - Pipeline by Pfizer Inc, H1 2018

Sinusitis - Pipeline by Quorum Innovations LLC, H1 2018

Sinusitis - Pipeline by Therabron Therapeutics Inc, H1 2018

Sinusitis - Dormant Projects, H1 2018

Sinusitis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Sinusitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AmpliPhi Biosciences Corp
  • F. Hoffmann-La Roche Ltd
  • Knopp Biosciences LLC
  • Kyorin Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • OptiNose US Inc
  • Pfizer Inc
  • Quorum Innovations LLC
  • Therabron Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll